PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 727: Tumor specific induction of surface calreticulin by doxorubicin in pancreatic ductal adenocarcinoma.

View Full Paper
JWJasmine A. WattsRWR WATTSCPChloe La Prairie

Key Points

  • The study aims to explore if doxorubicin induces specific surface expression of calreticulin in pancreatic ductal adenocarcinoma.
  • Injected mouse 2838c3 PDAC cells subcutaneously into mice.
  • Administered two doses of doxorubicin or saline at 48-hour intervals.
  • Collected tumors and organs post-treatment for flow cytometry and immunofluorescence analyses.
  • Doxorubicin significantly increased surface calreticulin expression in PDAC tumors (3.0-fold increase; p < 0.05).
  • Immunofluorescence showed a 1.3-fold increase in calreticulin signal intensity (9623 AU ± 522.6 vs. 7341 AU ± 485.9; p = 0.0021).
  • No significant changes in calreticulin expression were observed in non-tumor tissues.

Abstract

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) accounts for most pancreatic cancer cases. Despite advances in surgery and chemotherapy, the 5-year survival rate is only 13%. The aggressive nature of PDAC combined with delayed diagnosis highlights the need for new targeted diagnostic and treatment strategies. Calreticulin (CALR) is an endoplasmic reticular chaperone protein that can translocate to the cell surface under stress conditions such as chemotherapy. We hypothesized that systemic doxorubicin induces tumor specific surface translocation of CALR in PDAC. Methods Mouse 2838c3 PDAC cells were injected subcutaneously into mice. Once the tumors were palpable, the mice were treated with two intraperitoneal injections of doxorubicin (10 mg/kg) or saline, spaced 48 hours apart and then sacrificed. Tumors and major organs (heart, lung, kidney, pancreas, colon, small intestine, liver, and spleen) were harvested and prepared for either flow cytometry or immunofluorescence analyses. For flow cytometry, tumors and organs were dissociated into non-permeabilized, fixed single cell suspensions and stained with a fixable live/dead dye and an anti-CALR antibody. Immunofluorescence staining was performed under non-permeabilized conditions using an anti-CALR antibody and wheat germ agglutinin (WGA) membrane mask. Signal intensity was quantified in Fiji as integrated density/area. Unpaired t-test with Welch’s correction was utilized for comparison. Results Doxorubicin treatment significantly increased surface CALR expression in PDAC tumors compared to saline-treated controls as measured by flow cytometry (3.0-fold increase; p 0.05) and immunofluorescence (1.3-fold increase; 9623 AU ± 522.6 vs. 7341 AU ± 485.9, mean ± SEM, p = 0.0021). Increases in surface CALR were consistent across biological replicates. Importantly, there were no significant differences in CALR expression after doxorubicin induction in non-tumor tissues such as liver, spleen, heart, lung, kidney, pancreas, colon, or small intestine via flow cytometry or immunofluorescence analyses. Citation Format: Jasmine A. Watts, Ronald Watts, Chloe La Prairie, John B. Rose, Rachael Guenter. Tumor specific induction of surface calreticulin by doxorubicin in pancreatic ductal adenocarcinoma abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 727.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Watts et al. (2026) studied this question.

synapsesocial.com/papers/69d1fcc0a79560c99a0a260fhttps://doi.org/10.1158/1538-7445.am2026-727
Ask AI
Helpful
Bookmark
Share
View Full Paper